|
FDA to review new drug application for Spiriva Respimat for asthma
Healio Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for tiotropium bromide inhalation spray for long-term maintenance of patients aged 12 years and older with asthma, according to a press release. Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug … |
View full post on asthma – Google News